Nrx pharmaceuticals notes new data on brilife® covid-19 vaccine effectiveness against delta variant posted by israel institute for biological research

Radnor, pa., nov. 26, 2021 (globe newswire) -- nrx pharmaceuticals (nasdaq: nrxp), today notes that the israel institute for biological research (iibr) has posted scientific results from an initial sample of phase 2 vaccinated patients in order to assess the potential effectiveness of the brilife® vaccine against the delta variant of the sars-cov-2 virus. blood (sera) from an initial sample of 11 trial participants demonstrated effective neutralizing antibodies against the original “wild-type” coronavirus and was tested for antibodies to the delta variant. of the eleven tested samples, ten were found to neutralize the delta variant1. the antibody levels are displayed in the scientific manuscript.
NRXP Ratings Summary
NRXP Quant Ranking